Sign Up Today and Learn More About Humacyte Stock
Invest in or calculate the value of your shares in Humacyte or other pre-IPO companies through EquityZen's platform.
Humacyte Stock
Regenerative Medical Technology Company
Humacyte, Inc. develops products for vascular disease and replacement of anatomical conduits. It offers human tissue-based products called human acellular vessels (HAV) for regenerative medicine and vascular surgery applications. The company was incorporated in 2004 and is headquartered in Morrisville, North Carolina.
About Humacyte Stock
Founded
2004
Headquarters
Morrisville, NC, US
Total Funding
436M
Industries
Software, Data and Analytics, Artificial Intelligence
Humacyte, Inc. develops products for vascular disease and replacement of anatomical conduits. It offers human tissue-based products called human acellular vessels (HAV) for regenerative medicine and vascular surgery applications. The company was incorporated in 2004 and is headquartered in Morrisville, North Carolina.
Humacyte Press Mentions
Stay in the know about the latest news on Humacyte
Science Translational Medicine Publishes Results That Humacyte’s “Human Acellular Vessels Recellularize and Evolve into Living Blood Vessels following Human Implantation”
Business Wire • Mar 27, 2020
Humacyte Founder Laura Niklason, M.D., Ph.D. Elected to National Academy of Engineering
Business Wire • Mar 02, 2020
Humacyte Awarded ‘Large Project Prototype of the Year’ from The Medical Technology Enterprise Consortium
Business Wire • Apr 08, 2019
Humacyte Appoints Chris Fang Chief Medical Officer
xconomy • Mar 08, 2019
Humacyte Promotes Jeffrey Lawson to Chief Executive
xconomy • Jun 25, 2018
Investors in Humacyte
Discover investors in Humacyte stock and explore their portfolio companies
Humacyte Management
Leadership team at Humacyte
Chief Executive Officer
Jeffrey Lawson
Chief Financial Officer
Douglas Blankenship
Join now and verify your accreditation status to gain access to:
- Humacyte current valuation
- Humacyte stock price
- Available deals in Humacyte and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in Humacyte stock?
Accredited investors can buy pre-IPO stock in companies like Humacyte through EquityZen funds. These investments are made available by existing Humacyte shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Humacyte stock?
Shareholders can sell their Humacyte stock through EquityZen's private company marketplace. EquityZen's network includes over 320K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 42K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
